Evidence map›Paper›PMID 37939296›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

LncRNAs-circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers.

Shanshan Liu, Benzheng Jiao, Hongguang Zhao, Xinyue Liang, Fengyan Jin, Xiaodong Liu, Ji-Fan Hu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Lipid metabolism in homeostasis and disease.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 3 countries.

Shanshan LiuKey Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital, Jilin University, Changchun, 130021, China.
Benzheng JiaoNHC Key Laboratory of Radiobiology (Jilin University), School of Public Health, Jilin University, Changchun, 130021, China.
Hongguang ZhaoNuclear Medicine Department, First Hospital, Jilin University, Changchun, 130021, China.
Xinyue LiangHematology Department, First Hospital, Jilin University, Changchun, 130021, China.
Fengyan JinHematology Department, First Hospital, Jilin University, Changchun, 130021, China.
Xiaodong LiuNHC Key Laboratory of Radiobiology (Jilin University), School of Public Health, Jilin University, Changchun, 130021, China.
Ji-Fan HuKey Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Cancer Center, First Hospital, Jilin University, Changchun, 130021, China.ORCID 0000-0002-2174-0361
Jilin University · CN

Funding

California Institute of Regenerative Medicine RT2-01942Innovative Program of National Natural Science Foundation of China 82050003National Key Research and Development Program of China 2018YFA0106902National Natural Science Foundation of China 31871297National Natural Science Foundation of China 32000431National Natural Science Foundation of China 81874052National Natural Science Foundation of China 82371872Natural Science Foundation of Jilin Province 20200201309JCScientific Research Project of the Education Department of Jilin Province JJKH20231241KJ
6 · The paper itself

Abstract

As one of novel hallmarks of cancer, lipid metabolic reprogramming has recently been becoming fascinating and widely studied. Lipid metabolic reprogramming in cancer is shown to support carcinogenesis, progression, distal metastasis, and chemotherapy resistance by generating ATP, biosynthesizing macromolecules, and maintaining appropriate redox status. Notably, increasing evidence confirms that lipid metabolic reprogramming is under the control of dysregulated non-coding RNAs in cancer, especially lncRNAs and circRNAs. This review highlights the present research findings on the aberrantly expressed lncRNAs and circRNAs involved in the lipid metabolic reprogramming of cancer. Emphasis is placed on their regulatory targets in lipid metabolic reprogramming and associated mechanisms, including the clinical relevance in cancer through lipid metabolism modulation. Such insights will be pivotal in identifying new theranostic targets and treatment strategies for cancer patients afflicted with lipid metabolic reprogramming.

Indexed as

NeoplasmsRNA, Long NoncodingEpigenesis, GeneticHumansLipidsMetabolic ReprogrammingRNA, CircularLipidsRNA, CircularRNA, Long NoncodingcancercholesterolcircRNAsfatty acidslipid metabolic reprogramminglncRNAs

Identifiers

PMID37939296
PMCPMC10767464
OpenAlexW4388485358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.